Keyword: Sandoz

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.

Hoping to expand its hospital portfolio in Japan, the Novartis generics unit is buying Aspen Pharmacare's operations there for up to €400 million.

In eyeing Novartis' deal to sell assets to Aurobindo, the Federal Trade Commission is reportedly delving into a lawsuit the generics maker faces.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.

Back in 2016, FDA stiff-armed Novartis and its Neulasta biosimilar. Three long years and one new study later, the company finally has its approval.

FTC review delays Sandoz-Aurobindo generics deal. Manufacturing questions push back Zolgensma decision in Japan. AZ expects mid-teens China growth.

What's taking Novartis' Sandoz and Aurobindo so long in their $1 billion U.S. generics oral solids and dermatology deal? FTC happened.

Altogether, seven foreign pharmas won bids in the expanded government drug purchase scheme versus only two in the original "4+7" pilot.

Novartis quickly pivoted from halting distribution of its generic Zantac drugs to recalling them because they contain a suspected carcinogen.